- Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC
- Additional podium presentation to provide updates from long-term evaluation of Padeliporfin VTP in intermediate-risk prostate cancer
“We are excited for the opportunity to share positive updates from the ENLIGHTED trial, which we believe will continue to reinforce Padeliporfin VTP’s potential to shift the treatment paradigm as a promising non-invasive option for patients with low-grade UTUC,” said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. “We also look forward to presenting results from longer-term evaluation of Padeliporfin VTP in intermediate-risk prostate cancer, where our mechanism of action is already well-understood in low-risk disease. ImPact continues to progress evaluation of Padeliporfin VTP in LG UTUC and other solid tumor indications, and we anticipate completing enrollment of the ENLIGHTED trial in 2nd half of 2025.”
Podium and Poster Session Details:
Clinical Profile:
- Poster Title: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC): ENLIGHTED Phase 3 Study
- Presenter: Vitaly Margulis, Professor of Urologic Oncology, University of Texas Southwestern
- Medical Center
- Poster Number: IP-12-14
- Session Title: Bladder Cancer: Upper Tract Transitional Cell Carcinoma
- Session Date & Time: April 27, 2025, 1:00 PM
- Podium Session Title: 48-Month Follow up of Results of the PCM-204 Phase 2b Trial of Partial-Gland Ablation for Men with Intermediate-Risk Prostate Cancer with Padeliporfin (WST11 or Tookad) Vascular-Targeted Photodynamic Therapy
- Presenter: Jonathan Fainberg, Urologic Surgeon, Memorial Sloan Kettering Cancer Center
- Podium Session Number: PD19-06
- Session Date and Time: April 27, 2025, 4:10 PM